Discontinued — last reported Q4 '23
Merck & Co. Weighted Average Exercise Price of Vested and Expected to Vest Options increased by 3.1% to $87.73 in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 3.1%, from $85.10 to $87.73. Over 4 years (FY 2021 to FY 2025), Weighted Average Exercise Price of Vested and Expected to Vest Options shows an upward trend with a 7.8% CAGR.
Helps investors understand the average strike price of the company's long-term equity incentive overhang.
This is the weighted average exercise price for the total pool of vested and expected-to-vest stock options. It serves a...
Consistent with long-term compensation strategy and historical grant pricing.
weighted_avg_exercise_price_vested_expected| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $64.90 | $70.09 | $76.63 | $85.10 | $87.73 |
| QoQ Change | — | +8.0% | +9.3% | +11.1% | +3.1% |
| YoY Change | — | +8.0% | +9.3% | +11.1% | +3.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.